ENDRA Life Sciences Inc. (NASDAQ:NDRA) Sees Significant Growth in Short Interest

ENDRA Life Sciences Inc. (NASDAQ:NDRA) was the recipient of a large growth in short interest in June. As of June 30th, there was short interest totaling 42,119 shares, a growth of 92.3% from the June 15th total of 21,904 shares. Currently, 3.7% of the company’s shares are sold short. Based on an average daily trading volume, of 81,330 shares, the short-interest ratio is presently 0.5 days.

Institutional Trading of ENDRA Life Sciences

An institutional investor recently bought a new stake in ENDRA Life Sciences stock. Altium Capital Management LLC purchased a new stake in shares of ENDRA Life Sciences Inc. (NASDAQ:NDRA) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 51,900 shares of the company’s stock, valued at approximately $235,000. ENDRA Life Sciences makes up 0.9% of Altium Capital Management LLC’s investment portfolio, making the stock its 17th biggest position. Altium Capital Management LLC owned 6.92% of ENDRA Life Sciences as of its most recent SEC filing. Hedge funds and other institutional investors own 1.19% of the company’s stock.

ENDRA Life Sciences Price Performance

Shares of ENDRA Life Sciences stock opened at $4.99 on Friday. The business has a 50-day simple moving average of $5.11 and a 200 day simple moving average of $4.59. ENDRA Life Sciences has a one year low of $2.96 and a one year high of $9.85. The firm has a market capitalization of $6.34 million, a price-to-earnings ratio of -0.61 and a beta of -0.06.

ENDRA Life Sciences (NASDAQ:NDRA) last announced its quarterly earnings results on Friday, May 15th. The company reported ($1.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.23) by $0.14. On average, sell-side analysts expect that ENDRA Life Sciences will post -4.11 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on NDRA shares. Ascendiant Capital Markets lowered their price objective on shares of ENDRA Life Sciences from $27.00 to $25.00 and set a “buy” rating for the company in a research note on Monday, June 1st. Weiss Ratings restated a “sell (e+)” rating on shares of ENDRA Life Sciences in a report on Monday, April 20th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $25.00.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.